Bayer Aktiengesellschaft (BAYRY) Stock Price & Analysis
Bayer Aktiengesellschaft (BAYRY) closed at USD 12.39 on Thursday, October 22, 2026, down 0.88% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.5; the Oct 22, 2026 session ranged USD 12.28–12.4 on volume of 42,603 shares. Market capitalization is $48.69B, with a 52-week range of USD 7.48–15.23 (OQX). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BAYRY.md
Key facts (BAYRY)
- 1 of 80 tracked superinvestors hold BAYRY (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 15.9 (range 15.3–16.68).
- Total return with dividends: 1Y +56.3% vs S&P 500 +14.9%; 5Y -4.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.16, revenue estimate $10.00B.
Superinvestors (SEC 13F-HR, Q2 2026) (BAYRY)
1 of 80 tracked investors hold BAYRY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Kahn Brothers | Kahn Brothers Group | 13.26% | $74.8M | Unchanged |
Analysts (BAYRY)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 15.9 (low 15.3, high 16.68).
Total return (dividends reinvested) (BAYRY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +56.3% | -4.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +56.5% | -0.9% |
| Volatility (annualized) | 41.5% | 36.8% |
| Max drawdown | -31.2% (Feb 2026→Jun 2026) | -71.4% (May 2022→Dec 2024) |
BAYRY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.16 | $0.16 | +1.1% | $10.00B | 1 |
| Next quarter (ends Dec 2026) | $0.07 | $0.02 | +232.4% | $11.83B | 1 |
| Current fiscal year (ends Dec 2026) | $1.28 | $1.16 | +10.2% | $45.87B | 2 |
| Next fiscal year (ends Dec 2027) | $1.34 | $1.24 | +8.5% | $47.05B | 2 |
Key Statistics (as of October 23, 2026 at 10:38 UTC)
| Price | USD 12.39 |
|---|---|
| Change | ▼ 0.88% (down) |
| Previous Close | USD 12.5 |
| Open | USD 12.28 |
| Day Range | USD 12.28 – 12.4 |
| 52-Week Range | USD 7.48 – 15.23 |
| Volume | 42,603 shares |
| Market Cap | $48.69B |
| Exchange | OQX |
Technical Analysis (BAYRY)
Nexqual's technical model rates BAYRY "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.41 (neutral) |
| vs SMA50 | Below (USD 13.55) |
| MACD | -0.38 (negative) |
Analyst Ratings (BAYRY)
Wall Street analysts rate BAYRY "Buy" based on 4 analysts, with a mean price target of USD 15.9 (range USD 15.3–16.68), per Nexqual as of October 23, 2026 at 10:38 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 15.9 |
| High Target | USD 16.68 |
| Low Target | USD 15.3 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (BAYRY)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $10.00B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.27 vs est 0.25 ▲ beat |
| 2026-03-31 | USD 0.79 vs est 0.62 ▲ beat |
| 2025-12-31 | USD 0.18 vs est 0.16 ▲ beat |
| 2025-09-30 | USD 0.17 vs est 0.13 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financials & Fundamentals (BAYRY)
| Total Revenue | $45.38B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.20% |
| Gross Margin | +60.46% |
| Operating Margin | +9.19% |
| Profit Margin | -3.83% |
| ROE | -5.69% |
| Debt / Equity | 1.29 |
| Current Ratio | 1.04 |
| Total Cash | $5.08B |
| Total Debt | $38.43B |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financial Health Score (BAYRY)
Nexqual rates Bayer Aktiengesellschaft's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:38 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 9% (last 12 months) |
| Balance Sheet | Mixed — EUR 5.08B cash vs EUR 38.4B debt |
| Cash Flow | Solid — Operating cash flow EUR 4.78B (TTM) |
| Efficiency | Critical — ROE -6%, ROA 3.2% |
Ownership (BAYRY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.31% |
| Shares Outstanding | 3.93B |
| Float | 3.93B |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Leadership (BAYRY)
Bayer Aktiengesellschaft is led by William N. Anderson, Chairman of the Management Board & CEO, per Nexqual as of October 23, 2026 at 10:38 UTC.
| Chairman of the Management Board & CEO | William N. Anderson |
|---|---|
| President of the Pharmaceuticals Division & Member of the Board of Management | Stefan Oelrich |
| Chief Talent Officer, Labor Director & Member of Management Board | Heike Prinz |
| CFO & Member of Management Board | Judith Hartmann |
| Member of Management Board, Head of the Crop Science Division & President of Crop Science Division | Rodrigo Santos |
Major Backers & Investors (BAYRY)
Notable institutional backers of Bayer Aktiengesellschaft include Kahn Brothers Group Inc., Dodge & Cox Funds-Dodge & Cox Balanced Fund, according to Nexqual as of October 23, 2026 at 10:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kahn Brothers Group Inc. | 0.17% |
| Dodge & Cox Funds-Dodge & Cox Balanced Fund | 0.15% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIIB | Biogen Inc. | USD 253.84 | ▲ 5.34% |
| SNY | Sanofi | USD 41.96 | ▲ 2.42% |
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt